Interruption in the supply chain with Silapen 1 000 000 IU/7 ml oral suspension (phenoxymethypenicillin)
25.07.2014
Belupo d.d., the marketing authorisation holder for Silapen 1 000 000 IU/7 ml oral suspension (phenoxymethylpenicillin) has informed the Agency for Medicinal Products and Medical Devices about the intereruption in the supply chain of this medicine. The decision about the interruption of the supply chain has been brought due to commercial reasons and it is not associated with quality, efficacy or safe use of the medicine.
There are other authorised medicinal product from the same therapeutic group on the Croatian market to be used for patients’ needs.
HALMED will, upon wholesalers’ request approve enter/import of the substitute medicine of the same pharmaceutical form, not having marketing authorisation in Croatia, as determined by the prescribing doctor.
